Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients.

Kammerer S, Sokolowski A, Hackl H, Platzer D, Jahn SW, El-Heliebi A, Schwarzenbacher D, Stiegelbauer V, Pichler M, Rezania S, Fiegl H, Peintinger F, Regitnig P, Hoefler G, Schreibmayer W, Bauernhofer T.

Oncotarget. 2016 Dec 20;7(51):84705-84717. doi: 10.18632/oncotarget.13224.

2.

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration.

Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.

3.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
4.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.

Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.

5.

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J, Gould R, Symmans WF.

Mod Pathol. 2015 Jul;28(7):913-20. doi: 10.1038/modpathol.2015.53. Epub 2015 May 1.

6.

Prepectoral implant placement and complete coverage with porcine acellular dermal matrix: a new technique for direct-to-implant breast reconstruction after nipple-sparing mastectomy.

Reitsamer R, Peintinger F.

J Plast Reconstr Aesthet Surg. 2015 Feb;68(2):162-7. doi: 10.1016/j.bjps.2014.10.012. Epub 2014 Oct 16.

PMID:
25455288
7.

First experience using contrast-enhanced ultrasound to evaluate vascularisation of acellular dermal matrices after implant-based breast reconstruction.

Parvizi D, Haas F, Peintinger F, Hubmer M, Rappl T, Koch H, Schintler M, Spendel S, Kamolz LP, Wurzer P, Tuca A, Fuchsjaeger M, Weinke R.

Breast J. 2014 Sep-Oct;20(5):461-7. doi: 10.1111/tbj.12301. Epub 2014 Jul 7.

PMID:
25041092
8.

IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.

Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F.

Int J Cancer. 2015 Mar 1;136(5):1193-201. doi: 10.1002/ijc.29064. Epub 2014 Jul 10.

9.

Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.

Rordorf T, Hassan AA, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B; Central European Cooperative Oncology Group (CECOG); Swiss Group for Clinical Cancer Research (SAKK).

Breast. 2014 Oct;23(5):511-25. doi: 10.1016/j.breast.2014.05.023. Epub 2014 Jun 27.

PMID:
24986766
10.

Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?

Peintinger F.

Curr Opin Obstet Gynecol. 2014 Feb;26(1):21-6. doi: 10.1097/GCO.0000000000000041. Review.

PMID:
24346126
11.

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F.

Eur J Cancer. 2013 Jul;49(10):2277-83. doi: 10.1016/j.ejca.2013.01.034. Epub 2013 Mar 13.

PMID:
23490652
12.

The positive non-sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node.

Mazouni C, Reitsamer R, Rimareix F, Stranzl H, Uzan C, Garbay JR, Delaloge S, Peintinger F.

J Surg Oncol. 2012 Nov;106(6):703-7. doi: 10.1002/jso.23188. Epub 2012 Jun 4.

PMID:
22674094
13.

Clinical use of nomograms for breast cancer.

Peintinger F.

J Surg Oncol. 2011 Jun;103(8):745. doi: 10.1002/jso.21761. No abstract available.

PMID:
21544816
14.

Genomic index of sensitivity to endocrine therapy for breast cancer.

Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2010 Sep 20;28(27):4111-9. doi: 10.1200/JCO.2010.28.4273. Epub 2010 Aug 9.

15.

Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer.

Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF.

Cancer. 2010 Nov 1;116(21):4933-43. doi: 10.1002/cncr.25443.

16.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN.

J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2.

17.

Sentinel Node Biopsy in Breast Cancer: Clinical Implication - Standard of Care - Fututre Prospects.

Haid A, Kühn T, Goyal A, Tausch C, Peintinger F, Schrenk P, Gallowitsch H.

Breast Care (Basel). 2009;4(3):195-202. Epub 2009 Jun 17. No abstract available.

18.

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF.

Ann Oncol. 2008 Dec;19(12):2020-5. doi: 10.1093/annonc/mdn427. Epub 2008 Jul 29.

19.

Predictors of mastectomy in a certified breast center - the surgeon is an independent risk factor.

Reitsamer R, Menzel C, Glueck S, Hitzl W, Peintinger F.

Breast J. 2008 Jul-Aug;14(4):324-9. doi: 10.1111/j.1524-4741.2008.00592.x.

PMID:
18540955
20.

Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group.

Kroiss R, Winkler V, Kalteis K, Bikas D, Rudas M, Tea M, Fuerhauser C, Muhr D, Cerny H, Glueck S, Petru E, Concin H, Kubista E, Oefner P, Wagner T; Austrian Hereditary Breast and Ovarian Cancer Group.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1113-21. doi: 10.1007/s00432-008-0383-5. Epub 2008 Apr 8.

PMID:
18392852

Supplemental Content

Loading ...
Support Center